Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Novonesis (Novozymes) B's
Operating Income
for the
three
months ended in Mar. 2026 was MXN5,697 Mil. Novonesis (Novozymes) B's Interest Expense for the
three
months ended in Mar. 2026 was MXN-179 Mil.
Novonesis (Novozymes) B's interest coverage for the quarter that ended in Mar. 2026 was 31.78.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Novonesis (Novozymes) B's Interest Coverage or its related term are showing as below:
MEX:NSISN'
s Interest Coverage Range Over the Past 10 Years
Min: 8.63 Med: 42.32 Max: 313.07
Current: 18
MEX:NSISN's Interest Coverage is ranked better than 60.87% of 1237
companies
in the Chemicals industry
Industry Median: 10.26
vs MEX:NSISN: 18.00
Novonesis (Novozymes) B (MEX:NSISN) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Novonesis (Novozymes) B Interest Coverage Related Terms
Novonesis (Novozymes) B Interest Coverage Historical Data
* Premium members only.
The historical data trend for Novonesis (Novozymes) B's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:NSISN vs LIN, SHW, ECL: Interest Coverage Comparison
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B Interest Coverage vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's Interest Coverage falls into.
Novonesis (Novozymes) B Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (MEX:NSISN) has a Interest Coverage of 31.78 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novonesis (Novozymes) B and its competitors. This is 25% below median its historical median of 42.32. Over the past decade, Novonesis (Novozymes) B's Interest Coverage has ranged from 8.63 to 313.07. According to the industry distribution chart, Novonesis (Novozymes) B ranks #484 out of 1237 companies in the Chemicals industry, placing it in the top 39.1%.
Is Novonesis (Novozymes) B's Interest Coverage too high?
Novonesis (Novozymes) B's current Interest Coverage of 31.78 is 25% below median its 10-year median of 42.32. Over the past 10 years, this metric has ranged from a low of 8.63 to a high of 313.07. The Chemicals industry median Interest Coverage is 10.26. Novonesis (Novozymes) B's value of 31.78 is 209.7% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #484 out of 1237 companies in the Chemicals industry, which is above the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Interest Coverage compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #484 out of 1237 companies for Interest Coverage. This puts Novonesis (Novozymes) B in the upper half of its industry. The industry median Interest Coverage is 10.26. Novonesis (Novozymes) B's value of 31.78 is 209.7% above this benchmark. Historically, Novonesis (Novozymes) B's own Interest Coverage has ranged from 8.63 to 313.07 over the past decade. While the company's 10-year median is 42.32 vs. the industry median of 10.26, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Chemicals company?
The median Interest Coverage among Chemicals companies is 10.26, based on 1,237 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current Interest Coverage of 31.78 is 209.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median Interest Coverage is 10.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current Interest Coverage is 31.78, which is 25% below median its own 10-year median of 42.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Novonesis (Novozymes) B (MEX:NSISN) has a current Interest Coverage of 31.78. The stock's GF Value™ is MXN979.45, compared to a current price of MXN911.11 — trading 7% below its estimated fair value. The current Interest Coverage is 31.78, which is 25% below median its 10-year median of 42.32 and 209.7% above the Chemicals industry median of 10.26. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Novonesis (Novozymes) B (MEX:NSISN), the current Interest Coverage is 31.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (MEX:NSISN) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued.
The current stock price of MXN911.11 is trading 7% below its estimated GF Value™ of MXN979.45.
Key valuation signals for MEX:NSISN:
Interest Coverage: 31.78 (25% below median its 10-year median of 42.32)
GF Value™: MXN979.45 vs. price of MXN911.11 (7% below fair value)
Industry Position: 209.7% above the Chemicals median (#484 of 1237)
No single metric tells the full story. See the MEX:NSISN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score
Get the complete analysis for MEX:NSISN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NSISN has been successfully added to your 
